- Home
- KNSA vs CGAU Comparison
KNSA vs CGAU Comparison
Compare KNSA & CGAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | CGAU |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNSA | CGAU |
|---|---|---|
| Price | $41.52 | $14.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $51.33 | $14.17 |
| AVG Volume (30 Days) | 345.4K | ★ 900.2K |
| Earning Date | 10-28-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 1.41% |
| EPS Growth | N/A | ★ 236.39 |
| EPS | 0.47 | ★ 1.60 |
| Revenue | $597,973,000.00 | ★ $1,285,392,000.00 |
| Revenue This Year | $62.63 | $14.70 |
| Revenue Next Year | $29.93 | $12.63 |
| P/E Ratio | $89.09 | ★ $8.89 |
| Revenue Growth | ★ 55.68 | 2.66 |
| 52 Week Low | $17.82 | $5.41 |
| 52 Week High | $42.98 | $14.73 |
Technical Indicators
Market Signals| Indicator | KNSA | CGAU |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 71.55 |
| Support Level | $40.33 | $13.08 |
| Resistance Level | $42.32 | $14.73 |
| Average True Range (ATR) | 1.45 | 0.44 |
| MACD | -0.13 | 0.10 |
| Stochastic Oscillator | 56.68 | 77.97 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.